BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT03991442

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03991442
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03991442. Randomized; triple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2021-03-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
Acronym
FINAL
Condition
Essential Hypertension
Intervention (Drug)
Fimasartan/Amlodipine
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct03991442
Content hash
0bea2090caa37c5e0c7c0f9c638509eb727c8f467bd8c77ea84e6b99f88c7a0c